

## **Correction to Popova et al.**

When the article “Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study,” by Vanina Popova et al. (doi: 10.1176/appi.ajp.2019.19020172) was published online on May 21, 2019, and in the June 2019 issue, one of the percentages in Table 1 was misreported. The percentage of participants in the antidepressant plus placebo group who had been treated with three or more antidepressant medications should have been listed as 33.9%. This correction was made and the article was reposted on July 11, 2019.